Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Melissa Cushing

Clinical Pathology/Laboratory Medicine New York, NY Medical Doctor

NPI 1316024839 CMS profile 149530

525 E 68Th St, Box 69, New York, NY 10021

Open in the dashboard

General payments

$139,186

106 records reported · program years 2019–2025

Research payments

$17,495

Paid to them · 26 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$861,246 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Melissa Cushing of New York, NY is reported in the CMS Open Payments database as having received $139,186 across 106 general payments and $17,495 in research payments paid to them. Separately, studies naming them as principal investigator received $861,246 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Clinical Pathology/Laboratory Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52,262 33
2024 General $18,263 16
2023 General $40,449 38
2023 Research $2,475 2
2022 General $4,371 6
2022 Research $933 4
2021 General $9,350 4
2021 Research $4,550 8
2020 General $7,700 3
2020 Research $5,338 7
2019 General $6,790 6
2019 Research $4,200 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melissa Cushing
  • Clinical Pathology/Laboratory Medicine median
  • Middle half of Clinical Pathology/Laboratory Medicine
  • National median

In program year 2025, general payments to Melissa Cushing were reported at $52,262. Among 206 Clinical Pathology/Laboratory Medicine profiles paid that year, the median was $114 and the middle half received between $43 and $2,190.

Show as a table
Year Melissa Cushing Clinical Pathology/Laboratory Medicine median Middle half National median
2019 $6,790 $100 $25–$525 $163
2020 $7,700 $127 $24–$3,383 $114
2021 $9,350 $124 $28–$2,259 $132
2022 $4,371 $100 $36–$1,512 $149
2023 $40,449 $125 $30–$797 $160
2024 $18,263 $127 $30–$1,800 $164
2025 $52,262 $114 $43–$2,190 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cerus Corporation $38,670 29 payments
  2. CSL Behring $27,550 18 payments
  3. Octapharma USA, Inc. $22,697 23 payments
  4. Instrumentation Laboratory Company $18,106 16 payments
  5. Haemonetics Corporation $16,264 14 payments
  6. Grifols Shared Services North America, Inc. $15,584 3 payments
  7. Baxter Healthcare $124 1 payment
  8. HemoSonics LLC $103 1 payment
  9. Werfen USA LLC $87 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $85,507 22 payments
  2. Honoraria $24,320 8 payments
  3. Travel and Lodging $23,743 37 payments
  4. Food and Beverage $3,824 33 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $1,500 1 payment
  6. Education $179 3 payments
  7. Gift $112 2 payments
Products named General payments · program years 2019–2025
  1. INTERCEPT BLOOD SYSTEM FOR CRYOPRECIPITATION $25,035 13 payments
  2. RiaSTAP $19,135 11 payments
  3. OCTAPLAS $15,920 16 payments
  4. INTERCEPT BLOOD SYSTEM FOR PLATELETS $11,598 14 payments
  5. FIBRYGA $6,778 7 payments
  6. TEG6s HEMOSTASIS SYSTEM $2,800 1 payment
  7. DEVICE-TRANSFUSION $2,037 2 payments
  8. No Related Product $124 1 payment
  9. Kcentra $119 2 payments
  10. QUANTRA QPLUS SYSTEM $103 1 payment
  11. Other $163 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Octapharma USA, Inc. $17,495 26 payments

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$1,038

Medicare's payments for the services billed

Medicare patients

21

Average age 70

Services billed

22

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 62%
Ischemic heart disease 57%
Heart failure 52%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Pathology/Laboratory Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record